MedTrace Logo

Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma

NCT00095186 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-04-10

No results posted yet for this study

Summary

The purpose of this study is to determine if orally-administered recombinant human lactoferrin is effective in the treatment of advanced renal cell carcinoma (RCC) in patients who have failed at least one prior systemic therapy for RCC.

Conditions

  • Carcinoma, Renal Cell

Interventions

DRUG

Recombinant Human Lactoferrin

Sponsors & Collaborators

  • Agennix

    lead INDUSTRY

Principal Investigators

  • Ernest W. Yankee, Ph.D. · Agennix, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2007-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095186 on ClinicalTrials.gov